Britain’s competition regulator has dealt a blow to Sainsbury’s planned US$9.5 billion takeover of Walmart’s Asda, stating the supermarket groups are unlikely to be able to address its “extensive” concerns about the deal.
The Competition and Markets Authority (CMA) stated the proposed acquisition could result in consumers facing “higher prices, reduced quality and choice, and a poorer overall shopping experience across the UK,” and expressed skepticism that selling stores alone could fix those problems.
Walmart-owned Asda is the UK’s third-largest supermarket chain, while Sainsbury’s is second. The takeover, agreed in April, would create the market leader, overtaking Tesco. The companies have insisted the combination would lead to lower prices.
The CMA disagreed, identifying 629 areas where there could be a substantial lessening of competition in supermarkets, more than the 463 it identified in its initial investigation, and a further 290 areas where online competition could be reduced. There were smaller overlaps in convenience stores, where Asda is not a big participant, but it cited 132 locations where competition in petrol and diesel retailing could be reduced.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas